Most recent update: Monday, September 23, 2019 - 09:10

Bariatric News - Cookies & privacy policy

You are here

NAFLD diagnosis

New concepts for the diagnosis of NAFLD and personalised treatment

If patients suffer from fatty liver, positive effects can often be achieved with lifestyle intervention

An international team of researchers have proposed the use of a new diagnostic and therapeutic approaches for non-alcoholic fatty liver disease (NAFLD) in the clinic to enable a specific risk prognosis for possible secondary diseases. Professor Norbert Stefan and Professor Hans-Ulrich Häring - both from Tübingen University Hospital and the Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Zentrum München, a partner of the DZD, together with Professor Kenneth Cusi from the University of Florida (USA) have evaluated the most important data of NAFLD research and compiled them in a review article. The paper, ‘Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies’, has been published in the journal The Lancet Diabetes & Endocrinology,

More and more adults, as well as about 34 percent of obese children, suffer from NAFLD. An unhealthy lifestyle with little physical activity and a diet high in fat, sugar and fructose and/or a genetic predisposition can be the underlying caus. However, fatty liver includes a broad spectrum of liver conditions and involves more than just the liver itself. NAFLD is a complex and heterogeneous disease that can lead to various complications such as severe liver damage, type 2 diabetes and cardiovascular disease.

"In order to avoid these secondary diseases, fatty liver must be diagnosed in good time, and the respective risk for diseases of the liver, the heart and other organs must be precisely assessed. Then a personalised prevention and treatment can be developed," said first author, Professor Norbert Stefan.

But how can the fat content in the liver be accurately determined and how can liver damage such as inflammation and fibrosis be reliably detected? The use of simple indices or ultrasound examinations is suitable for this in primary care. Specialists such as hepatologists, endocrinologists and radiologists could perform further examinations such as special magnetic resonance imaging (MRI) if required.

"Not only patients with elevated liver enzymes should be examined for fatty liver, but also people with a disproportionate fat distribution, ie a high proportion of abdominal fat and/or a low proportion of fat around the hips and legs," said Professor Häring. In addition, the authors of the review recommend fatty liver screening also for people suffering from insulin resistance or type 2 diabetes.

If patients suffer from fatty liver, positive effects can often be achieved with lifestyle intervention. For example, a reduction of about five percent in weight can reduce the fat content in the liver by up to 30 percent. However, to reduce the risk of liver inflammation and fibrosis, a weight loss of about ten percent is required.

"If such weight loss cannot be achieved or is insufficient to improve NAFLD, pharmacological treatment should be considered," said Professor Cusi. To date, no drug has been approved for NAFLD. "However, under certain conditions such as diabetes and NAFLD or obesity and NAFLD, specific drugs can be used that have different effects on liver fat content, inflammation and fibrosis.”

Recent research suggests that genetic NAFLD is associated with a higher risk of liver fibrosis and liver cancer.

"However, unexpectedly, the same patients have a low risk of cardiovascular diseases. In order to be able to treat those affected patients properly, it is important to know whether a fatty liver is genetically determined," Professor Stefan added.

The authors of the review believe that in the future, the application of these concepts will enable a personalised risk prognosis and individualized treatment of NAFLD. In addition, researchers will be able to specifically develop lifestyle modification programmes and drugs for the respective subtypes based on the various aspects of this disease.

To access this article, please click here

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.